Metered-dose inhaler formulations with beclomethasone-17,21-dipropionate using the ozone friendly propellant R 134a

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 46, Issue 1, 1998, Pages 77-83

  Steckel, Hartwig ^a   Müller, Bernd W ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

Aerosol formulation; Beclomethasone dipropionate; CFC free; Fine particle fraction; Metered dose inhaler; Two stage impinger

Indexed keywords

ALCOHOL; BECLOMETASONE DIPROPIONATE; CHLOROFLUOROCARBON; NORFLURANE; OLEIC ACID; PROPELLANT;

AEROSOL; ARTICLE; DISPERSION; DRUG FORMULATION; DRUG SOLUBILITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METERED DOSE INHALER; PARTICLE SIZE; SUSPENSION;

AEROSOL PROPELLANTS; ANTI-ASTHMATIC AGENTS; BECLOMETHASONE; CHEMISTRY, PHARMACEUTICAL; HYDROCARBONS, FLUORINATED; NEBULIZERS AND VAPORIZERS;

EID: 0344937951     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0939-6411(97)00115-X     Document Type: Article

References (23)

1. Aerosol Consensus Statement, Chest 100 (1991) 1106-1109.
2. H. Matthys, Inhalation delivery of asthma drugs, Lung (Suppl.) (1990) 645-652.
3. Dalby R.N., Byron P.R. Comparison of output particle size distributions from pressurized aerosols formulated as solutions or suspensions. Pharm. Res. 5:1988;36-39.
4. Molina M.J., Rowland F.S. Stratospheric sink for chlorofluoromethanes: chlorine catalysed destruction of ozone. Nature. 249:1974;810-812.
5. Montreal Protocol, Montreal protocol on substances that deplete the ozone layer, 1987.
6. Montreal Protocol, Report of the technology and economic assessment panel including recommendations on nominations for essential use production/consumption exemptions for ozone depleting substances, 1994.
7. Dalby R.N. Safety assessment of metered-dose inhalers containing flammable propellants. J. Biopharm. Sci. 3:1992;41-47.
8. Dalby R.N., Byron P.R. Metered-dose inhalers containing flammable propellants: perspectives and some safety evaluation procedures. Pharm. Technol. Eur. 3(1):1992;40-45.
9. Leach C.L. Approaches and challenges to use Freon propellant replacements. Aerosol Sci. Technol. 22:1995;328-334.
10. P.R. Byron, N.C. Miller, F.E. Blondino, J.E. Visich, G.H. Ward, Some aspects of alternative propellant solvency, in: R.N. Dalby, P.R. Byron, S.J. Farr (Eds.), Respiratory Drug Delivery IV, Interpharm Press, Buffalo Grove, 1994, pp. 231-242.
11. Boyd G. The continued need for metered-dose inhalers. J. Aerosol Med. 8(Suppl. 1):1995;9-12.
12. Dalby R.N., Byron P.R., Shephard H.R., Papadopoulos E. CFC-propellant substitution: P 134a as a potential replacement for P 12 in MDIs. Pharm. Technol. 2(3):1990;26-33.
13. Tansey I.P. The challenges in the development of metered-dose inhalation aerosols using ozone friendly propellants. Spray Technol. Marketing. 7:1994;26-29.
14. Ventraesca G.P. Clinical pharmacology of HFA 134a. J. Aerosol Med. 8(Suppl. 1):1995;35-39.
15. Meier M., Fischer F.X., Keller M., Halfmann H.J. Influence of alternative propellants on microbial viability in comparison to chlorofluorocarbons. Pharm. Ind. 58:1996;78-82.
16. Phillips E.M. Crystal growth-formulation dependence and early detection. J. Biopharm. Sci. 3:1992;11-18.
17. Soine W.H., Blondino F.H., Byron P.R. Chemical stability in pressurized inhalers formulated as solutions. J. Biopharm. Sci. 3:1992;41-47.
18. F.H. Blondino, P.R. Byron, Drug stability in non-aqueous solutions - influence of surfactant concentration, in: R.N. Dalby, P.R. Byron, S.J. Farr (Eds.), Respiratory Drug Delivery V, Interpharm Press, Buffalo Grove, 1996, pp. 125-131.
19. British Pharmacopoeia, Her Majesty's Stationary Office, London, 1993.
20. Polli G.P., Grim W.M., Bader F.A., Yunker M.H. Influence of formulation on aerosol particle size. J. Pharm. Sci. 58:1969;484-486.
21. Warren S.J., Farr S.J. Formulation of solution metered dose inhalers and comparison with aerosols emitted from conventional suspension systems. Int. J. Pharm. 124:1995;195-203.
22. Newman S.P., Moren F., Pavia D., Corrado O., Clarke S.W. The effects of changes in metered volume and propellant vapour pressure on the deposition of pressurized inhalation aerosols. Int. J. Pharm. 11:1982;337-344.
23. Harnor K.J., Perkins A.C., Wastie M., Wilson C.G., Sims E.E., Feely L.C., Farr S.J. Effect of vapour pressure on the deposition pattern from solution phase metered dose inhalers. Int. J. Pharm. 95:1993;11-16.